Trial Profile
A Phase 2b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study to Assess the Efficacy and Safety of Oral UK-390,957 in Men With Premature Ejaculation
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 19 Nov 2012
Price :
$35
*
At a glance
- Drugs UK 390957 (Primary)
- Indications Premature ejaculation
- Focus Therapeutic Use
- Sponsors Pfizer
- 30 Aug 2006 Status change
- 10 Dec 2005 New trial record.